Showing 561-570 of 23008 results for "".
FcRn: Same Class, Different Paths—Spot Agent Differentiators
https://reachmd.com/programs/cme/fcrn-same-class-different-pathsspot-agent-differentiators/54778/Explore treat-to-target strategies and FcRn inhibitor use to guide outcomes-driven management of generalized myasthenia gravis.Understanding Accelerated Biological Aging in Pediatric MS
https://reachmd.com/programs/neurofrontiers/accelerated-biological-aging-pediatric-ms/54240/Emerging evidence shows that children with multiple sclerosis exhibit accelerated biological aging. Learn more about the potential implications with Dr. Jennifer Yang, who spoke about this topic at the 2026 ACTRIMS Forum. She's an Assistant Professor of Neurosciences at the UC San Diego School of MeAdvancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
https://reachmd.com/programs/cme/advancing-bispecific-antibodies-upstream-in-the-treatment-paradigm-of-multiple-myeloma/49263/Review emerging evidence supporting earlier use of bispecific antibodies in multiple myeloma, with a focus on efficacy, safety, and optimizing patient outcomes.Evidence Builds for Cell-Based Influenza Vaccines
https://reachmd.com/programs/medical-industry-feature/evidence-cell-based-influenza-vaccines/36269/Randomized controlled trials have shown data supporting the safety and efficacy of cell-based influenza vaccines in adults and children.1-4 However, effectiveness studies have historically relied on outcomes based on clinical diagnosis of influenza-like illness rather than test-confirmed influenza.5Quick and Accurate Research Evaluation for Busy Clinicians
https://reachmd.com/programs/partners-in-practice/quick-and-accurate-research-evaluation-for-busy-clinicians/6256/As medicine takes an increasingly evidence-based approach to care, it's more important than ever for busy clinicians to be able to evaluate the benefits and risk-reduction associated with new treatments and medications. This week's guest, Tom Bartol, nurse practitioner at the Richmond Area Health CeAdvances in Treatment of Hypoparathyroidism: Importance of Genetic Testing for Autosomal Dominant Hypocalcemia Type 1
https://reachmd.com/programs/cme/advances-in-treatment-of-hypoparathyroidism-importance-of-genetic-testing-for-autosomal-dominant-hypocalcemia-type-1/36097/Tune in to explore ADH type 1 care! Learn to recognize clinical features, enhance your diagnosis with genetic testing, and assess emerging therapies.Why CELMoDs Matter in Myeloma
https://reachmd.com/programs/cme/why-celmods-matter-in-myeloma/36558/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityCase Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
https://reachmd.com/programs/cme/case-application-frontline-insightstackling-newly-diagnosed-myeloma/36573/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityNext-Generation Innovations: The Future of CELMoDs in Myeloma
https://reachmd.com/programs/cme/next-generation-innovations-the-future-of-celmods-in-myeloma/36575/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityData Dive: Clinical Evidence Behind CELMoDs
https://reachmd.com/programs/cme/data-dive-clinical-evidence-behind-celmods/36568/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity